ClinicalTrials.gg
CompletedNCT01780844Updated Nov 21, 2025

A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients

A Phase 2 interventional study of ASKP1240 and Tacrolimus in Kidney Transplantation, sponsored by Astellas Pharma Global Development, Inc.. Completed at 42 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2014, 12 years 4 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Aug 2016.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of ASKP1240, an anti-CD40 monoclonal antibody, for the prophylaxis of organ rejection after kidney transplantation. This study will compare the efficacy of basiliximab induction, ASKP1240, mycophenolate mofetil (MMF), and steroids [calcineurin inhibitor (CNI) avoidance] to the standard of care immunosuppressive regimen (basiliximab induction + tacrolimus + MMF + steroids). In addition, the study will compare the efficacy of basiliximab induction, ASKP1240, tacrolimus and steroids [CNI minimization-MMF avoidance] to the standard of care immunosuppressive regimen (basiliximab induction + tacrolimus + MMF + steroids).

Read the detailed description

Subjects will be followed for 6 months. Upon completion of the first 6 months of the study, subjects may participate in the Long Term Extension period of the study. Subjects will remain on their original treatment arm up to three years post-transplant (and / or Sponsor discontinues development or the subject no longer wishes to participate in the study).

02

Conditions studied

  • Kidney Transplantation

Keywords

  • Kidney Transplantation
  • de novo Kidney Transplantation
  • ASKP1240
03

In context

Lead sponsor

Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.

Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is a recipient of a de novo kidney from a living or deceased donor

Exclusion criteria

Exclusion Criteria:

  • Subject has induction therapy, other than study-assigned basiliximab, planned as part of initial regimen
  • Subject has previously received or is receiving an organ transplant other than a kidney
  • Subject will receive a solitary kidney from a deceased donor \< 5 years of age
  • Subject will receive a kidney with an anticipated cold ischemia time (CIT) of > 30 hours
  • Subject will receive a kidney that meets both Extended Criteria Donor (ECD) and Donation after Cardiac Death (DCD) criteria. Note: a kidney that meets either ECD or DCD criteria is eligible for inclusion
  • Subject will receive an ABO incompatible donor kidney
  • Subject has a current calculated panel reactive antibody (cPRA) level >50%
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
149 participants (actual)

Study arms

  • Active comparator
    Standard of Care

    Basiliximab induction + Tacrolimus + MMF + Corticosteroids

    Drug: Tacrolimus · Drug: Mycophenolate Mofetil (MMF) · Drug: Basiliximab · Drug: Methylprednisone · Drug: Prednisone

  • Experimental
    CNI avoidance

    Basiliximab induction + ASKP1240 + MMF + Corticosteroids

    Drug: ASKP1240 · Drug: Mycophenolate Mofetil (MMF) · Drug: Basiliximab · Drug: Methylprednisone · Drug: Prednisone

  • Experimental
    CNI minimization-MMF avoidance

    Basiliximab induction + ASKP1240 + Tacrolimus + Corticosteroids

    Drug: ASKP1240 · Drug: Tacrolimus · Drug: Basiliximab · Drug: Methylprednisone · Drug: Prednisone

Interventions

06

What researchers measure

Primary outcomes

  1. Biopsy-proven acute (T or B cell) rejection (BPAR) (Banff 2007 Grade ≥ 1) by local review

    Time frame: 6 months

Secondary outcomes

  1. Glomerular Filtration Rate (GFR)

    GFR is based on Modification of Diet in Renal Disease (4 variable-MDRD) criteria

    Time frame: 6 months

  2. Patient Survival

    Subject survival is defined as any subject who does not die during the study.

    Time frame: 6 months

  3. Graft Survival

    Graft survival is defined as any subject who does not experience graft loss during the study. Graft loss is defined as subject death, retransplantation, transplant nephrectomy, or the permanent return to dialysis (greater than 30 days).

    Time frame: 6 months

07

Study locations

42 sites
  • Site US10006
    Birmingham, Alabama 35233, United States
  • Site US10024
    Phoenix, Arizona 85054, United States
  • Site US10008
    Los Angeles, California 90057, United States
  • Site US10021
    Palo Alto, California 94304, United States
  • Site US10030
    San Diego, California 92123, United States
  • Site US10004
    San Francisco, California 94115, United States
  • Site US10003
    San Francisco, California 94143, United States
  • Site US10013
    Aurora, Colorado 80045, United States
  • Site US10007
    Atlanta, Georgia 30322, United States
  • Site US10041
    Augusta, Georgia 30912, United States
  • Site US10010
    Chicago, Illinois 60612, United States
  • Site US10018
    Chicago, Illinois 60612, United States
  • Site US10037
    Chicago, Illinois 60637, United States
  • Site US10015
    Lexington, Kentucky 40536, United States
  • Site US10045
    New Orleans, Louisiana 70112, United States
  • Site US10014
    Baltimore, Maryland 21201, United States
  • Site US10017
    Ann Arbor, Michigan 48109, United States
  • Site US10025
    St Louis, Missouri 63110, United States
  • Site US10022
    Livingston, New Jersey 07039, United States
  • Site US10031
    Buffalo, New York 14215, United States
  • Site US10034
    New York, New York 10029, United States
  • Site US10023
    New York, New York 10065, United States
  • Site US10019
    The Bronx, New York 10467, United States
  • Site US10036
    Chapel Hill, North Carolina 27599, United States
  • Site US10042
    Charlotte, North Carolina 28203, United States
  • Site US10016
    Durham, North Carolina 27710, United States
  • Site US10026
    Greenville, North Carolina 27834, United States
  • Site US10009
    Cincinnati, Ohio 45267, United States
  • Site US10040
    Cleveland, Ohio 44106, United States
  • Site US10032
    Cleveland, Ohio 44195, United States
  • Site US10027
    Harrisburg, Pennsylvania 17011, United States
  • Site US10038
    Pittsburgh, Pennsylvania 15213, United States
  • Site US10012
    Charleston, South Carolina 29425, United States
  • Site US10028
    Memphis, Tennessee 38104, United States
  • Site US10035
    Nashville, Tennessee 37232-4750, United States
  • Site US10001
    Dallas, Texas 75246, United States
  • Site US10002
    Fort Worth, Texas 76104, United States
  • Site US10029
    Houston, Texas 77030, United States
  • Site US10044
    Houston, Texas 77030, United States
  • Site US10033
    Salt Lake City, Utah 84132, United States
  • Site US10020
    Charlottesville, Virginia 22908, United States
  • Site US10005
    Madison, Wisconsin 53792, United States
08

References and documents

Publications

  • Harland RC, Klintmalm G, Jensik S, Yang H, Bromberg J, Holman J, Kumar MSA, Santos V, Larson TJ, Wang X. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study. Am J Transplant. 2020 Jan;20(1):159-171. doi: 10.1111/ajt.15591. Epub 2019 Oct 19. PubMed 31509331 ↗

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2013 to primary completion in Jun 2014, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2013
First posted
Jan 31, 2013
StartActual
Mar 5, 2013
Primary completionActual
Jun 30, 2014
CompletionActual
Jan 27, 2017
Results delay requested
Aug 16, 2016
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01780844
Responsible party
Sponsor
First posted
Jan 31, 2013
Start date
Mar 5, 2013
Primary completion
Jun 30, 2014
Completion
Jan 27, 2017
Last update
Nov 21, 2025

Study contacts

Senior Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bleselumab · Tacrolimus · Mycophenolic Acid

Start the discussion